UMM Logo

Universitas Muhammadiyah Malang


Free Download Journals Directory


International Journal Of Bilogical Sciences

.: Home > International Journal Of Bilogical Sciences > 2016 > Volume 12 Number 4 > Xinxin Zhang, Lei Du, Feifang Zhao, Qiuju Wang, Shiming Yang, Lin Ma

A Phase II Clinical Trial of Concurrent Helical Tomotherapy plus Cetuximab Followed by Adjuvant Chemotherapy with Cisplatin and Docetaxel for Locally Advanced Nasopharyngeal Carcinoma

Xinxin Zhang, Lei Du, Feifang Zhao, Qiuju Wang, Shiming Yang, Lin Ma
1. Department of Otolaryngology, Head and Neck Surgery, Chinese People Liberation Army (PLA) General Hospital, Beijing, China. 2. Department of Radiation Oncology, Chinese People Liberation Army (PLA) General Hospital, Beijing, China.  Corresponding authors: Dr. Xinxin Zhang, Department of Otolaryngology, Head and Neck Surgery, PLA General Hospital, 28 Fuxing Road, Beijing100853, China. Tel: +86-15910520109; FAX: +86-010-68241383; E-mail: zhangxinxin@301hospital.com.cn; xinxinzhang66@hotmail.com. Or Co- Correspondence: Dr. Lin Ma, Department of Radiation Oncology, Chinese PLA General Hospital, 28 Fuxing Road, Beijing 100853, China. Tel: +86-13911197589; FAX: +86-010-55499243; Email: malinpharm@sina.com.
Abstract :

Purpose: The present clinical trial was designed to evaluate the efficacy and safety of concurrent helical tomotherapy (HT) with cetuximab followed by adjuvant chemotherapy with docetaxel and cisplatin (TP) in the treatment of patients with locoregionally advanced nasopharyngeal carcinoma. Materials and Methods: This phase II clinical trial included 43 patients with Stage III/IV LANC (33 Stage III and 10 Stage IV). The treatment consisted of concurrent HT with cetuximab (400 mg/m2 loading dose and weekly 250mg/m2 ), followed by four cycles of chemotherapy [docetaxel (70 mg/m2 on Day 1) and cisplatin (40 mg/m2 on Days 1 and 2 every 3 weeks). Side effects were evaluated with CTCAE criteria (Common Terminology Criteria for Adverse Events 3.0). Results: The median follow-up duration was 48.0 months [95% confidence interval (CI) 41.7-58.0 months], the 2-year locoregional failure-free rate (LFFR), progression-free survival (PFS), distant failure-free rate (DFFR) and overall survival (OS) were 95.2%, 79.1%, 88.1% and 93.0% respectively; the 3-year LFFR, DFFR, PFS and OS were 92.7%, 85.6%, 72.0% and 85.7% respectively. The most common grade 3 toxicities were oropharyngeal mucositis (81.4%) and RT-related dermatitis (7.0%). No patients had more than grade 3 radiation related toxicities and no patients required nasogastric feeding. One patient experienced grade 3 osteonecrosis at 18 months after treatment. Conclusions: Concurrent HT with cetuximab followed by adjuvant chemotherapy with TP is an effective strategy for the treatment of LANC with encouraging survival rates and minimal side effects

Keywords :
Locally advanced nasopharyngeal carcinoma; Helical tomotherapy; Cetuximab; Adjuvant chemotherapy; adverse event.

Date Deposited : 16 Mar 2016 11:46

Last Modified : 16 Mar 2016 11:46

Official URL: http://www.ijbs.com/v12i4

Volume 12, Number 4, - 2016 , ISSN 1449-2288

Download:
Full Text Original
Abstract : pdf doc
Home | Peta Situs | Admissions | Student Research | E-Journal
Universitas Muhammadiyah Malang © 2011
Developed by Infokom UMM
Last Update : 13 December 2016 20:46Kumpulan file jurnal